



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Abiraterone acetate-d₃

Cat. No.:	HY-75054S1
CAS No.:	2122245-10-5
Molecular Formula:	C ₂₆ H ₃₀ D ₃ NO ₂
Molecular Weight:	394.56
Target:	Isotope-Labeled Compounds; Cytochrome P450
Pathway:	Others; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Abiraterone acetate-d₃ (CB7630-d₃) is deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598)^[1].

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. A O'Donnell, et al. Hormonal impact of the 17 α -hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. *British Journal of Cancer* volume 90, pages2317–2325 (2004)
- [3]. Lee GT, et al. Intracrine androgen biosynthesis in renal cell carcinoma. *Br J Cancer*. 2017 Mar 28;116(7):937-943.
- [4]. Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. *Cancer Res*. 2012 May 1;72(9):2176-82.
- [5]. Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. *Asian J Androl*. 2014 May-Jun;16(3):387-400.
- [6]. Li R, et al. Abiraterone inhibits 3 β -hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. *Clin Cancer Res*. 2012 Jul 1;18(13):3571-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA